Clear cell renal cell carcinoma Trials in Detroit, United States
Conditions / Clear cell renal cell carcinoma / Detroit, United States
Clear cell renal cell carcinoma has been the subject of sustained clinical investigation across multiple research sites.
18 total trials for this combination
Showing top 10 of 18 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00335556 | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | COMPLETED | PHASE2 |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study | RECRUITING | PHASE1/PHASE2 |
| NCT01575548 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | ACTIVE_NOT_RECRUITING | — |
| NCT03793166 | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | ACTIVE_NOT_RECRUITING | — |
| NCT00378703 | Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer | COMPLETED | PHASE2 |
| NCT03793166 | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | ACTIVE_NOT_RECRUITING | — |
| NCT00326898 | Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery | COMPLETED | PHASE3 |
| NCT01575548 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | ACTIVE_NOT_RECRUITING | — |
| NCT01198158 | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy | TERMINATED | PHASE3 |
| NCT01835158 | Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer | COMPLETED | PHASE2 |